New research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic ...
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.
Editas Medicines has signed a $238 million biobucks pact to combine Genevant Science’s lipid nanoparticle (LNP) tech with the ...
Le Centre de Référence sur les Agents Tératogènes (CRAT) est une structure publique indépendante de l’industrie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback